Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).
On April 14, 2025, Quantum BioPharma Ltd. announced that the Court of Appeal for Ontario dismissed a reconsideration motion by Dr. Raza Bokhari, resulting in awards totaling $180,000 in favor of the company. This follows a series of legal proceedings where Dr. Bokhari, a former CEO, contested his dismissal but was unsuccessful. Quantum BioPharma is now proceeding with the collection of awarded monies, which strengthens its financial position and underscores its legal standing in ongoing disputes.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative, metabolic, and alcohol misuse disorders. The company is actively engaged in the research and development of its lead compound, Lucid-MS, which targets multiple sclerosis, and retains significant ownership in Celly Nutrition Corp. for its OTC product, UNBUZZD.
YTD Price Performance: 70.10%
Average Trading Volume: 2,820,135
Technical Sentiment Signal: Buy
Current Market Cap: $15.76M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.